Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
In the second part of the interview at the BIO Investor forum, CEO Robert Blum discusses Cytokinetics’ deal with Amgen and long-range commercialization goals.